Agilent Technologies Stock: Is A Underperforming the Healthcare Sector?

Core Insights - Agilent Technologies, Inc. has a market capitalization of $35.2 billion and is a prominent provider of solutions in life sciences, diagnostics, and applied chemical markets [1] - The company operates through three main segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab, offering a wide range of instruments, consumables, software, and services [1] Company Performance - Agilent's stock has decreased over 18% from its 52-week high of $153.84, while it has risen 5.3% in the past three months, underperforming the Health Care Select Sector SPDR Fund's (XLV) 2.8% gain during the same period [3][4] - Year-to-date, Agilent's stock is down 6.1%, lagging behind XLV's 1.4% return, and has declined 9.1% over the past 52 weeks, compared to XLV's 10.1% decrease [4] - Following the Q3 2025 results on August 27, Agilent's shares climbed 5.3%, reporting adjusted EPS of $1.37 and revenue of $1.74 billion, exceeding estimates [5] Segment Performance - The Life Sciences and Diagnostics segment generated $670 million in sales, while the CrossLab unit delivered $744 million, indicating strong performance in these areas [5] - Agilent has raised its full-year revenue guidance to between $6.91 billion and $6.93 billion and tightened its EPS outlook to between $5.56 and $5.59, reflecting confidence in demand for its products [5] Competitive Landscape - In comparison, rival Eli Lilly and Company has seen a year-to-date decline of 1.8% and a 17.7% decrease over the past 52 weeks, which is better than Agilent's performance during the same timeframe [6]